KIDINS220 Inhibitors
Chemical inhibitors of KIDINS220 operate through various mechanisms to modulate its activity within signaling pathways. LY294002 and Wortmannin are two such inhibitors that target phosphoinositide 3-kinases (PI3K), which are essential for the activation of AKT. As AKT is involved in phosphorylating KIDINS220, the inhibition of PI3K by these compounds results in decreased AKT activation, thus leading to reduced phosphorylation and consequent activity of KIDINS220. Furthermore, U0126 and PD98059 work upstream of ERK1/2 in the MAPK/ERK pathway. Given that KIDINS220 is associated with this pathway, the action of these inhibitors leads to a decrease in ERK-mediated phosphorylation events on KIDINS220, which, in turn, inhibits its activity. Additionally, SB203580 targets the p38 MAP kinase, thereby attenuating the stress-induced activation of KIDINS220, while SP600125 inhibits the JNK pathway, which is also linked to the functional regulation of KIDINS220.
Furthermore, inhibitors like Y-27632, PP2, PF-562271, SL327, PF-4708671, and GSK2334470 intervene at different junctures in signaling cascades that impinge on KIDINS220 functionality. Y-27632, an inhibitor of the Rho-associated protein kinase (ROCK), can lead to diminished ROCK-mediated effects on KIDINS220. PP2, by selectively inhibiting Src family kinases, indirectly moderates the phosphorylation status and activation of KIDINS220. PF-562271, a focal adhesion kinase (FAK) inhibitor, disrupts signaling pathways critical for the role of KIDINS220 in neuronal growth. SL327 and PF-4708671, as inhibitors of MEK and p70 ribosomal S6 kinase (S6K1) respectively, curtail the activation of downstream effectors such as ERK1/2 and S6K1, which are known to interact with and regulate KIDINS220. GSK2334470, by inhibiting 3-phosphoinositide-dependent protein kinase-1 (PDPK1), exerts its effect by reducing the activation of AKT, thereby affecting the function of downstream targets like KIDINS220. Each of these inhibitors, by acting on specific kinases or pathways, can influence the activity of KIDINS220, which plays a pivotal role in neuronal function and signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators of the AKT pathway, known to phosphorylate KIDINS220 and affect its activity. Inhibition of PI3K leads to decreased AKT activation, thereby reducing KIDINS220 phosphorylation and its downstream signaling events. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that works by covalently binding to the catalytic site of PI3K, leading to the inhibition of AKT phosphorylation. This reduction in AKT activity diminishes the activation and function of downstream targets such as KIDINS220. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream of ERK1/2 in the MAPK/ERK pathway. Since KIDINS220 has been shown to interact with the MAPK/ERK pathway, inhibiting MEK1/2 could reduce ERK-mediated phosphorylation events on KIDINS220, thereby inhibiting its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that prevents the activation of MAPK/ERK kinase, indirectly leading to reduced activity of KIDINS220 due to lessened ERK-mediated phosphorylation which is necessary for KIDINS220's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which is involved in cellular stress responses and can intersect with pathways regulating KIDINS220. Inhibition of p38 MAP kinase can lead to reduced stress-induced activation of KIDINS220, thereby inhibiting its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in neuronal differentiation and survival pathways that can involve KIDINS220. Inhibition of JNK can lessen KIDINS220's role in these pathways, leading to functional inhibition. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a potent inhibitor of the Rho-associated protein kinase (ROCK), which can interact with neurite outgrowth and survival pathways involving KIDINS220. Inhibition of ROCK potentially leads to decreased interaction with KIDINS220, inhibiting its functional role in these pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases, which play a role in various signaling cascades that can regulate the function of proteins like KIDINS220. By inhibiting Src kinases, PP2 could indirectly reduce the phosphorylation and activation of KIDINS220. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $306.00 $465.00 $1102.00 | 3 | |
PF-562271 is a focal adhesion kinase (FAK) inhibitor. Given that KIDINS220 is involved in neuronal growth and regulation of synaptic stability, inhibition of FAK can disrupt signaling pathways that contribute to the functional role of KIDINS220 in these processes. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is an inhibitor of MEK, which prevents the activation of downstream ERK1/2. Since KIDINS220 has been implicated in ERK pathway signaling, SL327 can lead to diminished ERK-mediated effects on KIDINS220, effectively inhibiting its functionality. | ||||||